Document Detail


Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells.
MedLine Citation:
PMID:  19577537     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Introduction of biologics, such as infliximab, to the therapy of rheumatoid arthritis (RA) patients has revolutionized the treatment of this disease. However, biomarkers for predicting the efficacy of the drug at an early phase of treatment for selecting real responders have not been found. We here present predictive markers based on a thorough transcriptome analysis of white blood cells from RA patients. RNA from whole blood cells of consecutive 42 patients before the first infusion was analyzed with microarrays for training studies. Samples from the subsequent 26 consecutive patients were used for a prospective study. We categorized the results into no inflammation and residual inflammation groups using the serum C-reactive protein (CRP) level at 14weeks after the first infusion. The accuracy of prediction in our study was 65.4%.
Authors:
Motohiko Tanino; Ryo Matoba; Seiji Nakamura; Hideto Kameda; Kouichi Amano; Toshitsugu Okayama; Hayato Nagasawa; Katsuya Suzuki; Kenichi Matsubara; Tsutomu Takeuchi
Related Documents :
19877057 - Progressive multifocal leukoencephalopathy following rituximab treatment in a patient w...
24707337 - Amyloid β-related central nervous system angiitis presenting with an isolated seizure.
3668977 - The impact of rheumatoid arthritis and osteoarthritis: the activities of patients with ...
10519837 - Rhythmic auditory stimulation in gait training for patients with traumatic brain injury.
9923507 - A cross-sectional study into the prevalence of root caries in periodontal maintenance p...
24061197 - Ultrastructural findings in noncompaction prevail with neuromuscular disorders.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-07-03
Journal Detail:
Title:  Biochemical and biophysical research communications     Volume:  387     ISSN:  1090-2104     ISO Abbreviation:  Biochem. Biophys. Res. Commun.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-11     Completed Date:  2009-08-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372516     Medline TA:  Biochem Biophys Res Commun     Country:  United States    
Other Details:
Languages:  eng     Pagination:  261-5     Citation Subset:  IM    
Affiliation:
DNA Chip Research Inc, Yokohama 230-0045, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / pharmacology*,  therapeutic use
Antirheumatic Agents / pharmacology*,  therapeutic use
Arthritis, Rheumatoid / drug therapy,  genetics*
C-Reactive Protein / analysis
Gene Expression / drug effects
Gene Expression Profiling
Humans
Leukocytes / drug effects*,  metabolism
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells.
Next Document:  Acute cold exposure-induced down-regulation of CIDEA, cell death-inducing DNA fragmentation factor-a...